ProShare Advisors LLC Lowers Stake in Halozyme Therapeutics, Inc. $HALO

ProShare Advisors LLC lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 73.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 10,065 shares of the biopharmaceutical company’s stock after selling 27,918 shares during the period. ProShare Advisors LLC’s holdings in Halozyme Therapeutics were worth $524,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Redhawk Wealth Advisors Inc. raised its holdings in shares of Halozyme Therapeutics by 14.8% in the 2nd quarter. Redhawk Wealth Advisors Inc. now owns 37,419 shares of the biopharmaceutical company’s stock valued at $1,947,000 after buying an additional 4,827 shares during the period. Intech Investment Management LLC grew its position in Halozyme Therapeutics by 9.9% in the 1st quarter. Intech Investment Management LLC now owns 153,199 shares of the biopharmaceutical company’s stock valued at $9,776,000 after acquiring an additional 13,789 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt increased its stake in Halozyme Therapeutics by 78.0% during the second quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 102,000 shares of the biopharmaceutical company’s stock worth $5,305,000 after purchasing an additional 44,700 shares during the period. Shelton Wealth Management LLC acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth about $843,000. Finally, Focus Partners Wealth lifted its position in shares of Halozyme Therapeutics by 57.8% during the first quarter. Focus Partners Wealth now owns 120,815 shares of the biopharmaceutical company’s stock worth $7,709,000 after purchasing an additional 44,260 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling

In related news, CFO Nicole Labrosse sold 2,227 shares of the company’s stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $77.95, for a total value of $173,594.65. Following the completion of the transaction, the chief financial officer directly owned 22,079 shares of the company’s stock, valued at $1,721,058.05. This represents a 9.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $69.13, for a total transaction of $1,382,600.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares in the company, valued at $50,721,994.47. This represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 110,227 shares of company stock worth $8,028,955 over the last 90 days. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $70.25 on Thursday. The company has a market cap of $8.26 billion, a P/E ratio of 16.08, a PEG ratio of 0.35 and a beta of 1.18. The firm has a fifty day moving average price of $69.93 and a 200 day moving average price of $63.41. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 12 month low of $44.10 and a 12 month high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. The company had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.Halozyme Therapeutics’s quarterly revenue was up 22.1% on a year-over-year basis. During the same period last year, the firm earned $1.27 earnings per share. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HALO has been the topic of several recent research reports. Citizens Jmp upped their target price on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research note on Tuesday, November 4th. Leerink Partners upgraded shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target for the company in a research note on Tuesday, October 14th. JMP Securities increased their price objective on Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a research note on Wednesday, August 6th. Zacks Research cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Finally, Benchmark upped their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Seven research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $75.10.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.